Does codeine inhibit CYP2D6?

Indeed, codeine has been reported to be devoid of analgesic activity in patients that exhibit the CYP2D6 PM phenotype or when CYP2D6 is inhibited with quinidine. 35 Table 2 lists CYP2D6 inhibitors that may interact with codeine.

What is polymorphism of CYP2D6?

The polymorphism of the enzyme results in poor, intermediate, efficient or ultrarapid metabolisers (UMs) of CYP2D6 drugs. It is plausible that the UM genotype, where more than one active gene on one allele occurs, is the outcome of selective dietary selection in certain populations in North East Africa.

What does a poor metabolizer of CYP2D6 mean?

Genetics of CYP2D6 Patientswho are poor metabolizers (individuals with no CYP2D6 activity) or ultrarapid metabolizers (individuals with genetically elevated CYP2D6 activity) can have markedly altered response to drugs that are CYP2D6 substrates. Note that ethnic differences exist in CYP2D6 activity.

What is the role of CYP2D6?

The CYP2D6 enzyme catalyses the metabolism of a large number of clinically important drugs including antidepressants, neuroleptics, some antiarrhythmics, lipophilic β-adrenoceptor blockers and opioids.

What happens when you inhibit CYP2D6?

CYP2D6 Inhibitors Drugs that inhibit CYP2D6 activity are likely to increase the plasma concentrations of certain medications, and, in some cases, adverse outcomes will occur (see Table 3 below right for a list of known inhibitors).

What percentage of drugs are metabolized by CYP2D6?

CYP2D6 metabolizes around 25% of currently prescribed drugs, including various antidepressants, neuroleptics, beta-blockers, opioids, antiemetics, and antiarrhythmics.

What drug should not be given to a patient that is a poor CYP2D6 metabolizer?

If testing is performed, patients who are ultrarapid or poor metabolizers of CYP2D6 should avoid codeine use (and possibly tramadol, hydrocodone, and oxycodone) because of the potential for increased toxicity or lack of effectiveness.

What is metabolized by CYP2D6?

Does CYP2D6*10 alter the pharmacokinetics of codeine and its metabolites?

Genetic polymorphisms in CYP2D6 are associated with diminished pain relief and/or severe opioid side effects. In Chinese individuals, CYP2D6*10 is the most common allele with reduced enzyme activity. In this study, we investigated the effect of this allele on the pharmacokinetics of codeine and its metabolites.

How is CYP2D6 involved in the pathophysiology of opioid analgesia?

For codeine and hydrocodone, CYP2D6 activity is the required first step in the pathway of opioid analgesic effect, converting the prodrug to morphine or hydromorphone, respectively.

What are the substrates of CYP2D6?

The enzyme is largely non-inducible and metabolizes approximately 25% of current drugs. Typical substrates for CYP2D6 are largely lipophilic bases and include some antidepressants, antipsychotics, antiarrhythmics, antiemetics, beta-adrenoceptor antagonists (beta-blockers) and opioids.

Does the CYP2D6 phenotype affect the response to flecainide?

Since flecainide is mainly eliminated through renal excretion, and both R- and S-flecainide possess equivalent potency for sodium channel inhibition, the CYP2D6 phenotype has a minor impact on the response to flecainide.